Business Description
Orchestra BioMed Holdings Inc
NAICS : 541714
SIC : 2833
ISIN : US68572M1062
Total Employee Number:
86Description
Orchestra BioMed Holdings Inc is a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships with medical device companies. The company's flagship product candidates are Atrioventricular Interval Modulation Therapy (AVIM Therapy) for the treatment of hypertension, the risk factor for death, and Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the cause of mortality. It has one reportable segment, which consists of the development of clinical and preclinical product candidates through risk-reward sharing partnerships with medical device companies.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 5.96 | |||||
Equity-to-Asset | 0.41 | |||||
Debt-to-Equity | 0.39 | |||||
Debt-to-EBITDA | -0.29 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -3.53 | |||||
Beneish M-Score | 5.72 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 84.3 | |||||
3-Year EBITDA Growth Rate | -1.5 | |||||
3-Year EPS without NRI Growth Rate | -2.6 | |||||
3-Year FCF Growth Rate | -3.1 | |||||
3-Year Book Growth Rate | -17.3 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 37.37 | |||||
9-Day RSI | 39.05 | |||||
14-Day RSI | 41.78 | |||||
3-1 Month Momentum % | -8.28 | |||||
6-1 Month Momentum % | -1.24 | |||||
12-1 Month Momentum % | 29.13 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.03 | |||||
Quick Ratio | 7.01 | |||||
Cash Ratio | 6.89 | |||||
Days Inventory | 521.66 | |||||
Days Sales Outstanding | 0.9 | |||||
Days Payable | 13021.89 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -21.7 | |||||
Shareholder Yield % | -5.86 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 99.46 | |||||
Operating Margin % | -167.96 | |||||
Net Margin % | -166.96 | |||||
EBITDA Margin % | -166.16 | |||||
FCF Margin % | -168.3 | |||||
OCF Margin % | -166.59 | |||||
ROE % | -175.51 | |||||
ROA % | -64.71 | |||||
ROIC % | -464.64 | |||||
3-Year ROIIC % | 178.52 | |||||
ROC (Joel Greenblatt) % | -1690.08 | |||||
ROCE % | -80.79 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 6.9 | |||||
PB Ratio | 5.3 | |||||
Price-to-Tangible-Book | 5.31 | |||||
EV-to-EBIT | -2.62 | |||||
EV-to-EBITDA | -2.64 | |||||
EV-to-Revenue | 4.39 | |||||
EV-to-Forward-Revenue | 299.17 | |||||
EV-to-FCF | -2.61 | |||||
Price-to-GF-Value | 0.11 | |||||
| Price-to-Net-Current-Asset-Value | 5.9 | |||||
| Price-to-Net-Cash | 6.2 | |||||
Earnings Yield (Greenblatt) % | -38.17 | |||||
FCF Yield % | -24.79 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:OBIO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Orchestra BioMed Holdings Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 32.724 | ||
| EPS (TTM) ($) | -0.97 | ||
| Beta | 1.3951 | ||
| 3-Year Sharpe Ratio | 0.17 | ||
| 3-Year Sortino Ratio | 0.29 | ||
| Volatility % | 81.47 | ||
| 14-Day RSI | 41.78 | ||
| 14-Day ATR ($) | 0.216435 | ||
| 20-Day SMA ($) | 3.99725 | ||
| 12-1 Month Momentum % | 29.13 | ||
| 52-Week Range ($) | 2.2 - 5.424 | ||
| Shares Outstanding (Mil) | 59.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Orchestra BioMed Holdings Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Orchestra BioMed Holdings Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 08:00 | In 115 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 114 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 22 days | ||
| General meeting for 2026 | 2026-06-23 12:00 | 4.08 (+1.24%) | ||
| Sidoti Events Small-Cap Virtual Investor Conference | 2026-06-18 13:00 | 3.87 (-0.77%) | ||
| Jefferies Global Healthcare Conference in New York | 2026-06-04 09:55 | 3.86 (-1.03%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 3.91 (-3.46%) | ||
| Annual report for 2025 | 2026-03-12 | 4.60 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-12 | 4.60 (+0.00%) | ||
| Barclays 28th Annual Global Healthcare Conference | 2026-03-11 08:00 | 4.64 (-1.28%) |
Show
Entries
Orchestra BioMed Holdings Inc Frequently Asked Questions
What is Orchestra BioMed Holdings Inc(OBIO)'s stock price today?
The current price of OBIO is $3.72. The 52 week high of OBIO is $5.42 and 52 week low is $2.20.
When is next earnings date of Orchestra BioMed Holdings Inc(OBIO)?
The next earnings date of Orchestra BioMed Holdings Inc(OBIO) is 2026-08-12 Est..
Does Orchestra BioMed Holdings Inc(OBIO) pay dividends? If so, how much?
Orchestra BioMed Holdings Inc(OBIO) does not pay dividend.
Guru Commentaries on NAS:OBIO
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Orchestra BioMed Holdings Inc
Insider Sell: Darren Sherman Sells 15,000 Shares of Orchestra BioMed Holdings Inc (OBIO)
Jul 02, 2026
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers